Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KM602 in advanced solid tumors
NCT05766527Phase 1Not yet recruiting
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- Apr 2023
- Primary completion
- Dec 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KM602 in solid tumor, melanoma and non-small cell lung cancer (NSCLC), sponsored by Xuanzhu Biopharmaceutical. Primary endpoints: Maximum Tolerated Dose at 15 months, Recommended Phase 2 Dose at 15 months and 1 more. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
KM602
03
Conditions
solid tumormelanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05766527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05766527.